Since increased levels of tumor-infiltrating lymphocytes (TILs) in HER-2+ BC have been associated with a higher rate of pCR, good prognosis and improved survival after neoadjuvant chemotherapy [52], an immunotherapeutic approach has also been proposed in the last few decades. Here, ERBB2 is linked to breast cancer.